Efficacy, Safety and Tolerability of Vidofludimus in Patients With Inflammatory Bowel Disease: The ENTRANCE Study
Klaus Herrlinger(Robert Bosch Hospital), Eduard F. Stange(John Radcliffe Hospital), Wolfgang Reindl(Technical University of Munich), Bernd Hentsch, Klaus Fellermann(Apple (Israel)), Stefanie Howaldt, Mircea Diculescu(Institutul Clinic Fundeni), А. М. Петров, R Voiosu, Bruno Dietrich(Glycotope (Germany)), Heinz Hartmann(Praxis für Humangenetik), Aldo Ammendola(MorphoSys (Germany)), Jan‐Michel Otte(Klinikum Links der Weser), Ulrike Strauch(University Hospital Regensburg), Andreas Sturm(German Red Cross), Rosen Nikolov(University Hospital St. Ivan Rilski), S Stoĭnov
Cited by 9
Related Papers
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566